Primary Antiphospholipid Syndrome–Associated Diffuse Alveolar Hemorrhage
Open Access
- 27 August 2013
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 66 (2) , 301-310
Abstract
Objective: Diffuse alveolar hemorrhage (DAH) is an uncommon complication of primary antiphospholipid syndrome (APS). We aimed to describe the clinical characteristics, treatment, and outcomes of primary APS–associated DAH in a single center.Methods: We conducted a retrospective review of all adults with primary APS–associated DAH evaluated at Mayo Clinic over a 15‐year period. DAH was defined as bilateral pulmonary infiltrates and bronchoalveolar lavage (BAL) fluid documenting progressively bloody returns and/or the presence of >20% hemosiderin‐laden macrophages. Patients with other causes of DAH were excluded.Results: Eighteen patients were identified (median age 43 years). Capillaritis was present in surgical lung biopsy samples of 3 patients. BAL differential cell counts revealed predominantly neutrophils. All patients were treated initially with glucocorticoids. Cyclophosphamide (CYC) was used in 8 patients; complete remission was achieved in 3 patients treated with CYC alone and in 1 patient receiving combination therapy with rituximab (RTX). RTX was used in 9 patients; 2 patients achieved remission with RTX alone, whereas 3 patients required combination therapy with CYC or mycophenolate mofetil (MMF). No patient achieved complete remission while receiving single therapy with MMF, azathioprine, or plasma exchange. Intravenous gamma globulin therapy was administered in 5 patients; no patient achieved control of the disease. Six patients died, all because of complications related to uncontrolled DAH or its therapy.Conclusion: We present the largest case series of primary APS–associated DAH reported in the literature. DAH carries a very poor prognosis and therapeutic options are limited. Immunosuppression with either CYC or RTX is associated with the highest likelihood of remission induction and should be considered early.Keywords
This publication has 32 references indexed in Scilit:
- Rituximab induces resolution of recurrent diffuse alveolar hemorrhage in a patient with primary antiphospholipid antibody syndromeLupus, 2011
- Successful treatment of a case of catastrophic antiphospholipid syndrome with autologous BMT: case report and review of literatureBone Marrow Transplantation, 2010
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patientsAnnals of the Rheumatic Diseases, 2006
- Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantationBlood, 2005
- Pulmonary CapillaritisSeminars in Respiratory and Critical Care Medicine, 2004
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999
- Induction of Experimental Antiphospholipid Antibody Syndrome in PL/J Mice Following Immunization With β2GPIAmerican Journal of Reproductive Immunology, 1997
- Mechanisms of Action of Antiphospholipid Antibodies in the Antiphospholipid SyndromeInternational Archives of Allergy and Immunology, 1995
- Intra-Alveolar Haemorrhage in the Anticardiolipin Antibody SyndromeScandinavian Journal of Rheumatology, 1991